Drug Profile


Alternative Names: SYR-472; SYR111472 succinate; TAK-472; Trelagliptin succinate; Zafatek

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PPD; Syrrx Inc
  • Developer 3SBio; Takeda
  • Class Antihyperglycaemics
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 01 Dec 2016 Takeda completes a phase-III trial in Type-2 diabetes mellitus (Adjunctive treatment) in Japan (PO) (NCT02324569)
  • 31 Jul 2015 3SBio files an IND application with the China FDA in China for Type-2 diabetes mellitus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top